Needham & Company
-
Needham & Company Maintains a 'Hold' on Watson Pharmaceuticals (WPI); Actavis Acquisition Big, But Easy Money Already Made
-
Needham & Company Maintains a 'Hold' on Watson Pharmaceuticals (WPI); Looking at Actavis
-
Needham & Company on Watson Pharma (WPI); Shares Continue Prochieve Retreat Though Key Expected 2012/13 Growth Levers Appear Largely Unchanged
-
Needham & Company Maintains a 'Hold' on Watson Pharmaceuticals (WPI); Path to Near-Term PROCHIEVE Approval Appears Cloudy as Efficacy Fails to Meet FDA Threshold
-
Notable 52-Week Highs and Lows of the Day 12/21: (CTAS) (CVS) (AMGN) High; (AMGN) (VECO) (CREE) Low
-
Needham & Company on Watson Pharmaceuticals (WPI): Deal With Amgen Couples WPI’s Checkbook With Biotech Icon’s Development Prowess
-
Needham & Company Maintains a 'Hold' on Watson Pharmaceuticals (WPI); Generics Again Carry the Day; Launch Calendar Suggests Continued Short-term EPS Upside
-
Needham & Company Maintains a 'Hold' on Watson Pharmaceuticals (WPI); FDA Approves Amphastar’s Long Forgotten ANDA for Generic Lovenox
-
Needham & Company maintains a 'Hold' on Watson Pharmaceuticals (WPI); Generic Business Strength Allows 2Q11 Results to “Beat” Expectations
-
Needham & Company on Impax Labs (IPXL); Lawsuit Appears to Confirm That Generic Concerta Opportunity Remains A Real But Distant Star On Horizon
-
Needham & Company Upgrades Watson Pharmaceuticals (WPI); FDA Comes Through Again with Approval of Generic Toprol XL
-
Needham & Company Maintains an 'Underperform' on Watson Pharmaceuticals (WPI); Shares Already Discount Turnaround Dynamics
-
Needham & Co Downgrades Watson Pharmaceuticals (WPI) to Underperform.
-
Needham & Co Initiates Coverage on Watson Pharmaceuticals (WPI)

